64 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development
Be the Best … on performance against strategic, corporate targets and the overall performance of the business over the year, 110% of the target bonus was awarded, which
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development
Be the Best … on performance against strategic, corporate targets and the overall performance of the business over the year, 110% of the target bonus was awarded, which
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
candidates we develop after KIMMTRAK in mUM.
Our product candidates utilize a novel mechanism of action and involve novel targets which may result … . IMC-P115C targets the same PRAME-A02 peptide and uses essentially the same CD3 end and T-cell-receptor, or TCR, specificity as IMC-F106C.
IMC-T119C
8-K
EX-99.2
IMCR
Immunocore Holdings plc
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
-P115C in the second quarter of 2024. This ImmTAC candidate was designed with the aim of improving patient convenience. IMC-P115C targets the same
8-K
EX-99.1
m3en9fvug7yna20
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.3
nr12n
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
4cswogy1xj5x47wbcp
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
dspgwnlch bw
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
2ot hfixxtd
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
9rassre2yjh9hl lkw9
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.3
4mi5vjs 9jeef91w0o
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
ko2pdfpay
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
iwki9664g
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
morxenx5ywydhmwz
18 Apr 23
Current report (foreign)
4:13pm
6-K
EX-99.1
288tt0w0x8mxhvn0
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K/A
EX-99.1
d82i0
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.1
f9t6d4e16xlu1htxhpvb
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.3
b0a91z1i63omgep3
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.1
xq09t06qj3sp43
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am